The study that includes healthy volunteers and patients with rheumatoid arthritis will be carried out at QPS BV facility in Groningen, Netherlands. The study will be conducted as a dose escalation study by beginning with a very low dose and then gradually increasing the dose. The study is planned to start in October.
“As planned, the clinical trial application has been approved and thus a very important milestone has been reached when Lipum has manage to go from preclinical to clinal development for our drug candidate SOL-116. I´m very proud of the team and everyone who has contributed to this success with great dedication", says Einar Pontén, CEO of Lipum.
For further information, please contact:
Einar Pontén, CEO
Mobile: +46 70 578 34 95
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.